Item 8.01 Other Events.

On September 24, 2012, Cytokinetics, Incorporated issued a press release announcing that it is participating in the launch of MyoKardia, Inc., a start-up company that is focused to genetic heart disease. MyoKardia is being funded by Third Rock Ventures with a $38 million Series A financing. Contemporaneous with the launch of MyoKardia, Cytokinetics has entered into a research collaboration with the company. Under the agreement, MyoKardia will fund activities and personnel at Cytokinetics in connection with an agreed research plan. In addition, Cytokinetics has obtained an equity position in MyoKardia as consideration for an assignment of patent rights related to compounds and the licensing of enabling know-how, both associated with Cytokinetics' cardiac sarcomere inhibitor program which is focused to the treatment of hypertrophic cardiomyopathies. Cytokinetics may also receive payments based on the achievement of preclinical, clinical and commercial milestones and may receive royalties on the sale of products that arise from the research.

The information in this Item 8.01 and a copy of this press release is being furnished as Exhibit 99.1 to this report on Form 8-K.

---

Top of the Form